Dr. Jim Wu is Founder, Chairman and CEO of Ark Biopharmaceutical. He has over 25 years of experience in pharmaceutical research and development. Prior to founding the company, Dr. Wu served as a senior director of Roche R&D Center (China) Ltd., where he participated in multiple drug discovery programs in virology, oncology, and metabolic diseases. Dr. Wu is a prolific scientist with over 65 research papers published in international peer reviewed journals and is a co-inventor of ziresovir. 

Dr. Wu obtained his PhD from Brown University and his bachelor's degree from University of Science and Technology of China. He was a post-doctoral fellow at Harvard Medical School and formerly served on the editorial board of Antimicrobial Agents and Chemotherapy, one of the major anti-infectious disease publications.

Dr. Haiqing Yuan is Chief Operating Officer of Ark Biopharmaceutical. Dr. Yuan has nearly 20 years of pre-clinical drug development and management experience in multinational pharmaceutical companies. Prior to joining Ark Biopharmaceutical, Dr. Yuan was a senior director at the international drug service unit of WuXi AppTec and, before then, a research investigator at Allergan, where he led multiple drug discovery programs. Dr.Yuan is an inventor with over 30 patents and a prolific author of papers and books.

He obtained his PhD from Virginia Polytechnic Institute and State University and his bachelor's degree from Fudan University. Dr. Yuan performed post-doctoral research at University of Notre Dame and Walther Cancer Institute.

Amos Chang is Chief Commercial Officer of Ark Biopharmaceutical. Amos obtained his bachelor and master degrees from National Taiwan University major in agricultural Chemistry /Microbiology. He also received MBA degree from IESE Business School in Spain. Before joining ArkBio, Amos worked 8 years for GSK in China and UK, heading new product global and China launch for respiratory products in COPD and Asthma, and also in charge of sales and marketing for nebulization in the respiratory BU. After GSK, Amos took the role of GM with Joincare Pharmaceutical, overseeing commercialization of inhalation medicines, and successfully launched 2 new products in China. Between 2020 and 2022, Amos worked at Chiesi China as BU Head of primary care, in which he drove significant business growth and developed business strategy for COPD new product launch and NRDL inclusion. Amos Chang has extensive experience with new product launch, market access, alliance management, marketing and business operation, as well as having a rich knowledge in pediatric and respiratory therapeutic areas.